Onco-Innovations' New Technology May Enhance Cancer Treatment

Onco-Innovations Limited has unveiled a promising technology targeting DNA repair processes in cancer cells. The new Polynucleotide Kinase 3'-Phosphatase (PNKP) inhibitor aims to disrupt DNA repair, making cancer cells more prone to radiation therapy. This approach could enhance the effectiveness of treatments and reduce chances of recurrence.

The implications for cancer care are significant. With around 1.8 million new cancer cases annually in the US, improved therapy effectiveness can lead to better clinical outcomes and potentially lower costs. Onco-Innovations plans to commence FDA Phase 1 clinical trials this year.

Further, Onco-Innovations announced a contract with Outside the Box Capital Ltd. for marketing initiatives. The company granted stock options to certain officers and consultants, reflecting its commitment to progress.